Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China.
J Hematol Oncol. 2018 Nov 20;11(1):130. doi: 10.1186/s13045-018-0676-3.
Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years. New drugs such as ibrutinib, idelalisib, and venetoclax have achieved great success in treating relapsed and refractory (R/R) CLL. In addition, with the development of immunotherapy, chimeric antigen receptor-engineered T cells (CAR-T) therapy, a novel adoptive immune treatment, has also become more and more important in treating R/R CLL. It combines the advantages of T cells and B cells via ex vivo gene transfer technology and is able to bind targets recognized by specific antibodies without antigen presentation, thus breaking the restriction of major histocompatibility complex. So far, there have been lots of studies exploring the application of CAR-T therapy in CLL. In this review, we describe the structure of chimeric antigen receptor, the preclinical, and clinical results of CAR-T therapy against CLL, along with its adverse events and advances in efficacy.
慢性淋巴细胞白血病（CLL）是一种常见的成人 B 细胞慢性淋巴增殖性疾病，近年来其治疗取得了巨大进展。伊布替尼、idelalisib 和 venetoclax 等新药在治疗复发和难治性（R/R）CLL 方面取得了巨大成功。此外，随着免疫疗法的发展，嵌合抗原受体修饰的 T 细胞（CAR-T）疗法作为一种新型的过继免疫治疗，在治疗 R/R CLL 中也变得越来越重要。它通过体外基因转移技术结合了 T 细胞和 B 细胞的优势，能够结合特异性抗体识别的靶标，而无需抗原呈递，从而打破了主要组织相容性复合体的限制。迄今为止，已有大量研究探索了 CAR-T 疗法在 CLL 中的应用。在这篇综述中，我们描述了嵌合抗原受体的结构、CAR-T 疗法治疗 CLL 的临床前和临床结果，以及其不良事件和疗效进展。
